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• Eradicating biofilm-related infections without mechanical biofilm dispersal remains a challenge 
• The contribution to tolerance of low-level resistance related to the over-expression of efflux systems has not been evaluated in 
biofilms 
• Combination therapies are still considered as an approach to enhance killing of biofilm-embedded cells and minimize the 
emergence of resistance  
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Introduction Methods 
Results  
                                          Conclusion  
Efficacy of ciprofloxacin and amikacin used separately and in combination, against P. aeruginosa planktonic and biofilm cultures 
Impact of efflux systems on antibiotic (ATB) efficacy in planktonic and biofilm cultures 
 The ciprofloxacin-amikacin combination enhances killing and prevents emergence of resistance for low-level resistant strains in planktonic cultures, but not in biofilm.  
 The low-level resistance conferred by MexCD-OprJ and MexXY-OprM efflux pumps may reduce intracellular antibiotic concentrations and hence facilitate the selection of high-level resistant mutants by target site mutations , 
     In planktonic conditions, we suggest that the MIC value of ciprofloxacin should be determined, and levofloxacin evaluated, in order to detect MexCD-OprJ overexpression.  
In biofilm, the lack of bacterial eradication was related to an antibiotic-recalcitrant population composed of persister cells, refractory to antibiotics used alone or in combination. No regrowth due to high-level resistant mutant was detected whatever the antibiotic/strain pair studied. 
 PAO1, a wild type clinical strain (WT), and 3 clinical strains overexpressing the efflux MexAB-OprM (AB), MexXY-OprM (XY) and MexCD-OprJ (CD)  
 Planktonic and 2-day-old biofilm (6-wells plate) cultures of P. aeruginosa 
 challenged with ciprofloxacin (4 mg/L) and amikacin (40 mg/L) separately, in combination, and successively  
 Number of viable and resistant cells determined on MH2 without ATB and supplemented with 4-fold MIC of ciprofloxacin or amikacin  
 Characterization of resistant mutants = ATB susceptibility, QRDR sequencing, and efflux pumps gene expression  
 Determination of ciprofloxacin and amikacin group’s MICs (by recovering surviving cells from biofilms on MH2 plates after 72 h of ATB exposure)  
 Measurement of ciprofloxacin and amikacin concentrations in the biofilm at the end of the ciprofloxacin and amikacin exposure 
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Figure 1. Planktonic time-kill assays with ciprofloxacin (a), amikacin (b) and the combination of ciprofloxacin and amikacin (c).  
The total cfu numbers are the mean value for three different experiments.  
GC: growth control 
Figure 2. Biofilm time-kill assays with ciprofloxacin, amikacin and the combination of ciprofloxacin and amikacin.  
The total cfu numbers are the mean value for three different experiments. 
GC, growth control; CIP, ciprofloxacin; AMK, amikacin 
 ≥3 log10 cfu/mL reduction after 4 h of ciprofloxacin or 
amikacin in all strains  
 Regrowth of high-level resistant mutants: 
- when CD was exposed to ciprofloxacin (mutations in the 
QRDR of GyrA [Thr-83->Ile] and ParC [Ser-80->Leu ]) 
- when XY was exposed to amikacin  
 Eradication with a ciprofloxacin + amikacin combination in 
XY and CD strains  
 Eradication with ciprofloxacin or amikacin in all the other 
strains 
 PAO1, WT, AB, and CD were susceptible to ciprofloxacin and amikacin 
 XY strain was intermediate to amikacin (CMI = 16 mg/L) 
 No mutation in the QRDR 
 No hypermutable strains 
 AB, CD and XY respectively overexpressed MexAB-OprM, MexCD-OprJ 
and MexXY-OprM 
 ≥3 log10 cfu/mL reduction in all strains after 8 h of ATB 
exposure (similar killing rates for all regimens [p>0.05]) 
 4 [3.62 – 4.17] log10 cfu/mL plateau in all strains and for all 
regimens after 8 h and until 72 h of ATB exposure 
 No MIC creep : group’s MICs for the surviving cells after 
72 h of ATB exposure unchanged compared to pre-
exposure MIC 
 Erratically, for all regimens including combination 
therapy, 4-fold MIC ciprofloxacin or amikacin resistant 
mutants isolated from detached biofilm: low density, no 
mutation in the QRDR, and no bacterial regrowth  
 Sequential ATB exposure: bacterial reduction after the 
first ATB exposure significantly higher than after the 
second ATB exposure (p<0.05) 
 Stable ATB concentrations along time: no ATB 
degradation according ciprofloxacin and amikacin 
concentration measurements 
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 Planktonic time-kill assay 
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